Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)

Ingrid Arevalo-Rodriguez, Nadja Smailagic, Marta Roqué I Figuls, Agustín Ciapponi, Erick Sanchez-Perez, Antri Giannakou, Olga L Pedraza, Xavier Bonfill Cosp, Sarah Cullum, Ingrid Arevalo-Rodriguez, Nadja Smailagic, Marta Roqué I Figuls, Agustín Ciapponi, Erick Sanchez-Perez, Antri Giannakou, Olga L Pedraza, Xavier Bonfill Cosp, Sarah Cullum

Abstract

Background: Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were estimated to be living with dementia. Some people with mild cognitive impairment (MCI) will progress to dementia but others remain stable or recover full function. There is great interest in finding good predictors of dementia in people with MCI. The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings.

Objectives: To determine the diagnostic accuracy of the MMSE at various thresholds for detecting individuals with baseline MCI who would clinically convert to dementia in general, Alzheimer's disease dementia or other forms of dementia at follow-up.

Search methods: We searched ALOIS (Cochrane Dementia and Cognitive Improvement Specialized Register of diagnostic and intervention studies (inception to May 2014); MEDLINE (OvidSP) (1946 to May 2014); EMBASE (OvidSP) (1980 to May 2014); BIOSIS (Web of Science) (inception to May 2014); Web of Science Core Collection, including the Conference Proceedings Citation Index (ISI Web of Science) (inception to May 2014); PsycINFO (OvidSP) (inception to May 2014), and LILACS (BIREME) (1982 to May 2014). We also searched specialized sources of diagnostic test accuracy studies and reviews, most recently in May 2014: MEDION (Universities of Maastricht and Leuven, www.mediondatabase.nl), DARE (Database of Abstracts of Reviews of Effects, via the Cochrane Library), HTA Database (Health Technology Assessment Database, via the Cochrane Library), and ARIF (University of Birmingham, UK, www.arif.bham.ac.uk). No language or date restrictions were applied to the electronic searches and methodological filters were not used as a method to restrict the search overall so as to maximize sensitivity. We also checked reference lists of relevant studies and reviews, tracked citations in Scopus and Science Citation Index, used searches of known relevant studies in PubMed to track related articles, and contacted research groups conducting work on MMSE for dementia diagnosis to try to locate possibly relevant but unpublished data.

Selection criteria: We considered longitudinal studies in which results of the MMSE administered to MCI participants at baseline were obtained and the reference standard was obtained by follow-up over time. We included participants recruited and clinically classified as individuals with MCI under Petersen and revised Petersen criteria, Matthews criteria, or a Clinical Dementia Rating = 0.5. We used acceptable and commonly used reference standards for dementia in general, Alzheimer's dementia, Lewy body dementia, vascular dementia and frontotemporal dementia.

Data collection and analysis: We screened all titles generated by the electronic database searches. Two review authors independently assessed the abstracts of all potentially relevant studies. We assessed the identified full papers for eligibility and extracted data to create two by two tables for dementia in general and other dementias. Two authors independently performed quality assessment using the QUADAS-2 tool. Due to high heterogeneity and scarcity of data, we derived estimates of sensitivity at fixed values of specificity from the model we fitted to produce the summary receiver operating characteristic curve.

Main results: In this review, we included 11 heterogeneous studies with a total number of 1569 MCI patients followed for conversion to dementia. Four studies assessed the role of baseline scores of the MMSE in conversion from MCI to all-cause dementia and eight studies assessed this test in conversion from MCI to Alzheimer´s disease dementia. Only one study provided information about the MMSE and conversion from MCI to vascular dementia. For conversion from MCI to dementia in general, the accuracy of baseline MMSE scores ranged from sensitivities of 23% to 76% and specificities from 40% to 94%. In relationship to conversion from MCI to Alzheimer's disease dementia, the accuracy of baseline MMSE scores ranged from sensitivities of 27% to 89% and specificities from 32% to 90%. Only one study provided information about conversion from MCI to vascular dementia, presenting a sensitivity of 36% and a specificity of 80% with an incidence of vascular dementia of 6.2%. Although we had planned to explore possible sources of heterogeneity, this was not undertaken due to the scarcity of studies included in our analysis.

Authors' conclusions: Our review did not find evidence supporting a substantial role of MMSE as a stand-alone single-administration test in the identification of MCI patients who could develop dementia. Clinicians could prefer to request additional and extensive tests to be sure about the management of these patients. An important aspect to assess in future updates is if conversion to dementia from MCI stages could be predicted better by MMSE changes over time instead of single measurements. It is also important to assess if a set of tests, rather than an isolated one, may be more successful in predicting conversion from MCI to dementia.

Conflict of interest statement

None known

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies.
Figure 3
Figure 3
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study.
Figure 4
Figure 4
Forest plot of 1 MMSE conversion to all‐cause dementia.
Figure 5
Figure 5
Baseline MMSE scores ‐ conversion from MCI to all‐cause dementia.
Figure 6
Figure 6
Forest plot of 2 MMSE conversion to ADD.
Figure 7
Figure 7
MMSE scores conversion from MCI to ADD.
Test 1
Test 1
MMSE Conversion to All‐cause Dementia.
Test 2
Test 2
MMSE Conversion to AD dementia.
Test 3
Test 3
MMSE Conversion to Vascular Dementia.

References

References to studies included in this review

    1. Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O. Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2008;25(6):544‐52. [PUBMED: 18535375]
    1. Chopard G, Vanholsbeeck G, Tio G, Pitard A, Binetruy M, Rumbach L, et al. Rapid screening of cognitive change in patients with questionable dementia using the Memory Impairment Screen and the Isaacs Set Test. Journal of the American Geriatrics Society 2009;57(4):703‐8. [PUBMED: 19220561]
    1. Conde‐Sala JL, Garre‐Olmo J, Vilalta‐Franch J, Llinas‐Regla J, Turro‐Garriga O, Lozano‐Gallego M, et al. Predictors of cognitive decline in Alzheimer's disease and mild cognitive impairment using the CAMCOG: a five‐year follow‐up. International Psychogeriatrics 2012;24(6):948‐58. [PUBMED: 22278151]
    1. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biological Psychiatry 2008;64(10):871‐9. [PUBMED: 18723162]
    2. Devanand DP, Pradhaban G, Liu X, Khandji A, Santi S, Segal S, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68(11):828‐36. [PUBMED: 17353470]
    1. Meguro K, Ishii H, Kasuya M, Akanuma K, Meguro M, Kasai M, et al. Incidence of dementia and associated risk factors in Japan: The Osaki‐Tajiri Project. Journal of the Neurological Sciences. 2007;260(1‐2):175‐82. [PUBMED: 17553526]
    2. Nakata E, Kasai M, Kasuya M, Akanuma K, Meguro M, Ishii H, et al. Combined memory and executive function tests can screen mild cognitive impairment and converters to dementia in a community: the Osaki‐Tajiri project. Neuroepidemiology 2009;33(2):103‐10. [PUBMED: 19494551]
    1. Meguro K, Ishii H, Kasuya M, Akanuma K, Meguro M, Kasai M, et al. Incidence of dementia and associated risk factors in Japan: The Osaki‐Tajiri Project. Journal of the Neurological Sciences. 2007;260(1‐2):175‐82. [PUBMED: 17553526]
    1. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. American Journal of Psychiatry 2005;162(4):667‐75. [PUBMED: 15800137]
    1. Modrego PJ, Gazulla J. The predictive value of the memory impairment screen in patients with subjective memory complaints: a prospective study. 2013; Vol. 15, issue 1. [2155‐7772: (Print)]
    1. Palmquist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, et al. Comparison of brief cognitive tests and CSB biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six‐year follow‐up study. PLoS One 2012;7(6):e38639. [PUBMED: 22761691]
    1. Pozueta A, Rodriguez‐Rodriguez E, Vazquez‐Higuera J L, Mateo I, Sanchez‐Juan P, Gonzalez‐Perez S, et al. Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test. BMC Neurology 2011;11:78. [PUBMED: 21702929]
    1. Xu G, Meyer JS, Thornby J, Chowdhury M, Quach M. Screening for mild cognitive impairment (MCI) utilizing combined mini‐mental‐cognitive capacity examinations for identifying dementia prodromes. International Journal of Geriatric Psychiatry. 2002;17(11):1027‐33. [PUBMED: 12404652]
References to studies excluded from this review
    1. Aevarsson O, Skoog I. A longitudinal population study of the mini‐mental state examination in the very old: relation to dementia and education. Dementia and Geriatric Cognitive Disorders 2000;11(3):166‐75. [PUBMED: 10765048]
    1. Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Archives of Neurology 2006;63(5):693‐9. [PUBMED: 16682538]
    1. Armas J. Clinical and neuropsychological risk factors to conversion from mild cognitive impairment to Alzheimer disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2009;5(4):P382.
    1. Brodaty H, Woodward M, Boundy K, Ames D, Balshaw R. Patients in australian memory clinics: baseline characteristics and predictors of decline at six months. International Psychogeriatrics 2011;23(7):1086‐96. [PUBMED: 21489344]
    1. Bruck A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. 2013; Vol. 40, issue 10:1567‐72. [1619‐7089: (Electronic)]
    1. Chan WC, Lam LC, Tam CW, Lui VW, Leung GT, Lee AT, et al. Neuropsychiatric symptoms are associated with increased risks of progression to dementia: A 2‐year prospective study of 321 Chinese older persons with mild cognitive impairment. Age and Ageing 2011;40(1):30‐5. [PUBMED: 21106558]
    1. Chilovi BV, Caratozzolo S, Mombelli G, Zanetti M, Rozzini L, Padovani A. Does reversible mci exist?. Alzheimer's & Dementia 2011;7(4):S548.
    1. Choi HJ, Lee DY, Seo EH, Sohn BK, Choe YM, Woo JI. Pib‐negative amnestic mild cognitive impairment related with low plasma apolipoprotein a1 level. Alzheimer's & Dementia 2013;9(4):P698.
    1. Cruz DM, Allen CM, Malmstrom TK, Tumosa N, Morley JE. Does the veterans affairs saint louis university mental status (SLUMS) exam predict the course of cognitive impairment?. Journal of the American Geriatrics Society 2012;60:S180.
    1. Devanand DP, Heertum RI, Kegeles LS, Liu X, Jin ZH, Pradhaban G, et al. (99m)Tc hexamethyl‐propylene‐aminoxime single‐photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease. American Journal of Geriatric Psychiatry 2010;18(11):959‐72. [PUBMED: 20808143]
    1. Devier DJ, Pelton GH, Tabert MH, Liu X, Cuasay K, Eisenstadt R, et al. The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease. International Journal of Geriatric Psychiatry 2009;24(12):1335‐42. [PUBMED: 19319929]
    1. Devier DJ, Villemarette‐Pittman N, Brown P, Pelton G, Stern Y, Sano M, et al. Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2010;30(3):238‐44. [PUBMED: 20847554]
    1. Ehrensperger MM, Berres M, Taylor KI, Monsch AU. Screening properties of the German IQCODE with a two‐year time frame in MCI and early Alzheimer's disease. International Psychogeriatrics 2010;22(1):91‐100. [PUBMED: 19747425]
    1. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSF‐phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69(24):2205‐12. [PUBMED: 18071141]
    1. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta‐amyloid1‐42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004;9(7):705‐10. [PUBMED: 14699432]
    1. Ito K, Mori E, Fukuyama H, Ishii K, Washimi Y, Asada T, et al. Prediction of outcomes in MCI with (123)I‐IMP‐CBF SPECT: a multicenter prospective cohort study. 2013; Vol. 27, issue 10:898‐906. [1864‐6433: (Electronic)]
    1. Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near‐normal cognition: risk factors and prognosis. Neurology 2012;79(15):1591‐8. [PUBMED: 23019264]
    1. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004;63(1):94‐100. [PUBMED: 15249617]
    1. Kruczyk M, Zetterberg H, Hansson O, Rolstad S, Minthon L, Wallin A, et al. Monte Carlo feature selection and rule‐based models to predict Alzheimer's disease in mild cognitive impairment. Journal of Neural Transmission 2012;119(7):821‐31. [PUBMED: 22573144]
    1. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011;76(17):1485‐91. [PUBMED: 21490316]
    1. Luck T, Luppa M, Wiese B, Breitner J, Scherer M, Maier W, et al. Mild cognitive impairment: Determinant patterns of short and long time to incident dementia. Alzheimer's & Dementia 2012;8(4):P151‐2.
    1. Madureira S, Verdelho A, Moleiro C, Ferro JM, Erkinjuntti T, Jokinen H, et al. Neuropsychological predictors of dementia in a three‐year follow‐up period: data from the LADIS study. 2010; Vol. 29, issue 4:325‐34. [PUBMED: 20389074]
    1. Mauri M, Sinforiani E, Corbetta S, Zucchella C, Giarracca V, Bono G. Progression to dementia of a population with aMCI: Clinical variables associated to conversion. Journal of Alzheimer's Disease 2011 Suppl 1:S66.
    2. Mauri M, Sinforiani E, Zucchella C, Cuzzoni MG, Bono G. Progression to dementia in a population with amnestic mild cognitive impairment: clinical variables associated with conversion. Functional Neurology 2012;27(1):49‐54. [PUBMED: 22687167]
    1. Meyer J, Xu G, Thornby J, Chowdhury M, Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. Journal of the Neurological Sciences 2002;201(1‐2):19‐25. [PUBMED: 12163189]
    1. Ott B, Grace J, Frakey L, Kelley P, Tremont G. Prediction of functional decline and conversion from mild cognitive impairment with the telephone‐administered Minnesota Cognitive Acuity Screen. Alzheimer's & Dementia 2013;9(4):P449.
    1. Ouchi Y, Akanuma K, Meguro M, Kasai M, Ishii H, Meguro K. Impaired instrumental activities of daily living affect conversion from mild cognitive impairment to dementia: the Osaki‐Tajiri Project. Psychogeriatrics 2012;12(1):34‐42. [PUBMED: 22416827]
    1. Paajanen T, Hanninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, et al. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study. 2014; Vol. 39, issue 3:679‐90. [1875‐8908: (Electronic)]
    2. Paajanen T, Hanninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, et al. Cerad memory composite score is an accurate neuropsychological predictor of progression to Alzheimer's disease: AddNeuroMed study. Alzheimer's & Dementia 2011;7(4):S259.
    1. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The Association of Neuropsychiatric Symptoms in MCI with Incident Dementia and Alzheimer Disease. American Journal of Geriatric Psychiatry 2013;21(7):685‐95. [PUBMED: 23567400]
    1. Serrano CM, Taragano F, Allegri RF, Krupitzki H, Martelli M, Feldman M, et al. Conversion predictors factors in mild cognitive impairment [Factores predictores de conversion en deterioro cognitivo leve (cohorte de seguimiento en CEMIC)]. Revista Neurologica Argentina 2007;32(2):75‐93.
    1. Tardif M, Roy M, Remi B, Laforce R, Verret L, Fortin M‐P, et al. Months backward test as a reliable predictor of cognitive decline in mild Alzheimer's disease. Alzheimer's & Dementia 2013;9(4):P741‐2.
    1. Rossum I, Burns L, Scheltens P, Soininen H, Wahlund LO, Hampel H, et al. High csf tau predicts rapid decline to Alzheimer's type dementia in mci subjects with abnormal CSF As1‐42. Alzheimer's & Dementia 2011;7(4):S548.
    1. Rossum IA, Visser PJ, Knol DL, Flier WM, Teunissen CE, Barkhof F, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. Journal of Alzheimer's Disease 2012;29(2):319‐27.
    1. Waldorff FB, Siersma V, Vogel A, Waldemar G. Subjective memory complaints in general practice predicts future dementia: a 4‐year follow‐up study. 2012; Vol. 27, issue 11:1180‐8. [1099‐1166: (Electronic)]
    1. Wong CH, Leung GT, Fung AW, Chan WC, Lam LC. Cognitive predictors for five‐year conversion to dementia in community‐dwelling Chinese older adults. 2013; Vol. 25, issue 7:1125‐34. [1741‐203X: (Electronic)]
    1. Zhang D, Shen D, Alzheimer's Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012;7(3):e33182. [PUBMED: 22457741]
References to ongoing studies
    1. Hall J, Plassman BI, Steffens D. Utility of NPI Scores predicting progression of CIND to dementia. American Journal of Geriatric Psychiatry 2012;20(3 Suppl 1):S8‐167.
Additional references
    1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 2011; Vol. 7, issue 3:270‐9.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM‐IV). Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Washington DC: American Psychiatric Association, 1994.
    1. Arevalo‐Rodriguez I, Pedraza OL, Rodríguez A, Sánchez E, Gich I, Solà I, et al. Alzheimer’s disease dementia guidelines for diagnostic testing: a systematic review. American Journal of Alzheimer's Disease and Other Dementias 2013;28(2):111‐9. [PUBMED: 23288575]
    1. Arevalo‐Rodriguez I, Smailagic N, Ciapponi A, Sanchez‐Perez E, Giannakou A, Roqué i Figuls M, at al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010783]
    1. Arevalo‐Rodriguez I, Segura O, Sola I, Bonfill X, Sanchez E, Alonso‐Coello P. Diagnostic tools for alzheimer´s disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviews. BMC Neurology 2014;14(1):183. [PUBMED: 25248284]
    1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005593; PUBMED: 16437532]
    1. Bleecker ML, Bolla‐Wilson K, Kawas C, Agnew J. Age‐specific norms for the Mini‐Mental State Exam. Neurology 1988;38(10):1565‐8. [PUBMED: 3419600]
    1. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2003;138(11):927‐37. [PUBMED: 12779304]
    1. Brayne C, Calloway P. The association of education and socioeconomic status with the Mini Mental State Examination and the clinical diagnosis of dementia in elderly people. Age and Ageing 1990;19(2):91‐6. [PUBMED: 2337015]
    1. Brayne C, Stephan BC, Matthews FE. A European perspective on population studies of dementia. Alzheimer's & Dementia 2011;7(1):3‐9. [PUBMED: 21255739]
    1. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004;16(2):129‐40. [PUBMED: 15318760]
    1. Chan Calvin CH, Fage Bruce A, Smailagic N, Gill Sudeep S, Herrmann N, Nikolaou V, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011414; : CD011414]
    1. Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation and cognitive training for early‐stage Alzheimer's disease and vascular dementia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003260; PUBMED: 14583963]
    1. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population‐based norms for the Mini‐Mental State Examination by age and educational level. Journal of the American Medical Association 1993;269(18):2386‐91. [PUBMED: 8479064]
    1. Davis Daniel HJ, Creavin Sam T, Noel‐Storr A, Quinn Terry J, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010460; : CD010460]
    1. Davis DHJ, Creavin ST, Yip JLY, Noel‐Storr AH, Brayne C, Cullum S. The Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementia disorders. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010775; : CD010775]
    1. Silva V, Hanwella R. Why are we copyrighting science?. BMJ 2010;341:c4738. [PUBMED: 20847026]
    1. Diniz BS, Yassuda MS, Nunes PV, Radanovic M, Forlenza OV. Mini‐Mental State Examination performance in mild cognitive impairment subtypes. International Psychogeriatrics 2007;19(4):647‐56. [PUBMED: 17502007]
    1. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger‐Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology 2010;9(11):1118‐27. [PUBMED: 20934914]
    1. Fage BA, Seitz DP, Gill SS, Herrmann N, Smailagic N, Chan CCH, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010860; : CD010860]
    1. Farina N, Isaac MGEKN, Clark Annalie R, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD002854.pub3; : CD002854]
    1. Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, et al. Diagnosis and treatment of dementia: 2. Diagnosis. Canadian Medical Association Journal 2008;178(7):825‐36. [PUBMED: 18362376]
    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112‐7. [PUBMED: 16360788]
    1. Folstein MF, Folstein SE, McHugh PR. "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189‐98. [PUBMED: 1202204]
    1. Glanville J, Cikalo M, Crawford F, Dozier M, McIntosh H. Handsearching did not yield additional unique FDG‐PET diagnostic test accuracy studies compared with electronic searches: a preliminary investigation. Research Synthesis Methods 2012;3(3):202‐13. [DOI: 10.1002/jrsm.1046]
    1. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Annals of Neurology 2008;64 Suppl 2:S81‐92. [PUBMED: 19127578]
    1. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta‐analysis of diagnostic accuracy studies. Biostatistics 2007;8(2):239‐51. [PUBMED: 16698768]
    1. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. European Journal of Neurology 2010;17(10):1236‐48. [PUBMED: 20831773]
    1. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):257‐62. [PUBMED: 21514247]
    1. Kokkinou M, Smailagic N, Noel‐Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. Plasma and cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010945]
    1. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Movement Disorders 2009;24(8):1103‐10. [PUBMED: 19353727]
    1. Leeflang MM, Moons KG, Reitsma JB, Zwinderman AH. Bias in sensitivity and specificity caused by data‐driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clinical Chemistry 2008;54(4):729‐37. [PUBMED: 18258670]
    1. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57:416‐8. [PUBMED: 8163988]
    1. Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008;56(8):1424‐33. [PUBMED: 18662209]
    1. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable‐risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Medicine 2009;6(11):e1000180. [PUBMED: 19901977]
    1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113‐24. [PUBMED: 8909416]
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863‐72. [PUBMED: 16237129]
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939‐44. [PUBMED: 6610841]
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263‐9. [PUBMED: 21514250]
    1. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5; PUBMED: 16625572]
    1. Mitchell AJ, Shiri‐Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. Journal of Neurology, Neurosurgery and Psychiatry 2008;79(12):1386‐91.
    1. Mitchell AJ. A meta‐analysis of the accuracy of the Mini‐Mental State Examination in the detection of dementia and mild cognitive impairment. Journal of Psychiatric Research 2009;43(4):411‐31. [PUBMED: 18579155]
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412‐4. [PUBMED: 8232972]
    1. Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2014;160(11):791‐7. [PUBMED: 24663815]
    1. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late‐onset dementia in a multicentre, community‐based population in England and Wales. Lancet 2001;357(0140‐6736 (Print)):169‐75. [PUBMED: 11213093]
    1. Nieuwenhuis‐Mark RE. The death knoll for the MMSE: has it outlived its purpose?. Journal of Geriatric Psychiatry and Neurology 2010;23(3):151‐7. [PUBMED: 20231732]
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999;56(3):303‐8. [PUBMED: 10190820]
    1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence‐based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1133‐42.
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256(3):183‐94. [PUBMED: 15324362]
    1. Petersen RC. Clinical practice: mild cognitive impairment. The New England Journal of Medicine 2011;364(23):2227‐34.
    1. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. Annals of Internal Medicine 2008;148(6):427‐34.
    1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's & Dementia 2013;9(1):63‐75.e2. [PUBMED: 23305823]
    1. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982‐90. [PUBMED: 16168343]
    1. Ritchie C, Smailagic N, Noel‐Storr Anna H, Takwoingi Y, Flicker L, Mason Sam E, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4]
    1. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology 1993;43(2):250‐60. [PUBMED: 8094895]
    1. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009132.pub2; : CD009132]
    1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. The New England Journal of Medicine 2009;360(22):2302‐9. [PUBMED: 19474427]
    1. Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia?. Alzheimer's & Dementia 2011;7(4):486‐9. [PUBMED: 21784357]
    1. Seitz DP, Fage BA, Chan CCH, Gill SS, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011415; : CD011415]
    1. Shiroky JS, Schipper HM, Bergman H, Chertkow H. Can you have dementia with an MMSE score of 30?. American Journal of Alzheimer's Disease and Other Dementias 2007;22(5):406‐15. [PUBMED: 17959876]
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. . 2011/04/26 2011; Vol. 7, issue 3:280‐92. [1552‐5279: (Electronic)]
    1. Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C. Early cognitive change in the general population: how do different definitions work?. Journal of the American Geriatrics Society 2007;55(10):1534‐40.
    1. Tombaugh TN, McIntyre NJ. The Mini‐Mental State Examination: a comprehensive review. Journal of the American Geriatrics Society 1992;40(9):922‐35. [PUBMED: 1512391]
    1. Trenkle DL, Shankle WR, Azen SP. Detecting cognitive impairment in primary care: performance assessment of three screening instruments. Journal of Alzheimer's Disease 2007;11(3):323‐35. [PUBMED: 17851183]
    1. Vacante M, Smailagic N, Sachpekidis C, Hyde C, Martin S, Ukoumunne O. The accuracy of 18FDG‐PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010632]
    1. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. Journal of Clinical Epidemiology 2011;64(6):602‐7. [PUBMED: 21075596]
    1. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529‐36. [PUBMED: 22007046]
    1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimer's & Dementia 2010;6(2):98‐103. [PUBMED: 20298969 ]
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004;256(3):240‐6. [PUBMED: 15324367]
    1. Yue J, Dong BR, Lin X, Yang M, Wu HM, Wu T. Huperzine A for mild cognitive impairment. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008827.pub2; : CD008827]
    1. Zhang S, Smailagic N, Hyde C, Noel‐Storr AH, Takwoingi Y, McShane R, Feng J. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2]

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir